IP Library › Granted Patent US 11,878,958
Granted Patent B2
US 11,878,958 · App. 18/323,700 · Granted Jan 23, 2024

MEK inhibitors and uses thereof

Inventors: Alfredo C. Castro (Somerville, MA); Michael J. Burke (Melrose, MA); Thomas A. Wynn (Lexington, MA); Sabine K. Ruppel (Cambridge, MA); Sergio L. Santillana Soto (Lexington, MA); Eric Haines (Andover, MA); Lan Xu (Wellesley, MA); Oksana Zavidij (Westminster, MA)
Assignee: Ikena Oncology, Inc.
C07D213/64A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,878,958
App. No.
18/323,700
Granted
Jan 23, 2024
Kind
B2
Abstract

The present disclosure provides MEK inhibitors, compositions thereof, and methods of using the same.

Claims (72)

1. A compound selected from:

I-1

I-2

I-37

I-40

I-41

I-42

I-43

I-45

I-46

I-54

I-55

I-64

I-112

I-133

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , which is:

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising a compound selected from:

I-1

I-2

I-37

I-40

I-41

I-42

I-43

I-45

I-46

I-54

I-55

I-64

I-112

I-133

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

12. The pharmaceutical composition of claim 11 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

13. The pharmaceutical composition of claim 11 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

14. The pharmaceutical composition of claim 11 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

15. The pharmaceutical composition of claim 11 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

16. The pharmaceutical composition of claim 11 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

17. The pharmaceutical composition of claim 11 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

18. The pharmaceutical composition of claim 11 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

19. The pharmaceutical composition of claim 11 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

20. The pharmaceutical composition of claim 11 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

21. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

22. The pharmaceutical composition of claim 11 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignments (2)
CHANGE OF NAME Recorded Dec 23, 2025
From: IKENA ONCOLOGY, INC.
To: IMAGENEBIO, INC.
Reel/Frame 073522/0031 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2023
From: CASTRO, ALFREDO C.; BURKE, MICHAEL J.; WYNN, THOMAS A.; RUPPEL, SABINE K.; SANTILLANA SOTO, SERGIO L.; HAINES, ERIC; XU, LAN; ZAVIDIJ, OKSANA
To: IKENA ONCOLOGY, INC.
Reel/Frame 064199/0340 →
Continuity (5)
Provisional Application 63488807 · Mar 7, 2023
Provisional Application 63479131 · Jan 9, 2023
Provisional Application 63375875 · Sep 16, 2022
Provisional Application 63345698 · May 25, 2022
Related Publication 20230382863A1 · Nov 30, 2023